Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye test and blood markers could spot dangerous pregnancy condition earlier

NCT ID NCT06122220

Diagnosis Sponsor: Saint Thomas Hospital, Panama Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at whether measuring the optic nerve sheath (the lining around the nerve connecting the eye to the brain) combined with blood tests for angiogenic factors can better diagnose severe pre-eclampsia in pregnant women. Pre-eclampsia is a serious condition that can harm both mother and baby. The researchers will measure these markers in 200 pregnant women between 24 and 40 weeks of pregnancy to see if they can predict complications like organ damage or poor fetal growth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Measurement of optic nerve sheath diameter and sFLT-1/PIGF index
What this could lead to
If successful, this approach could help doctors more accurately diagnose severe pre-eclampsia and predict complications, potentially improving outcomes for mothers and babies.
What could go wrong
This is an early-stage diagnostic study with 200 participants, so results may not apply to all pregnant women. The measurements may not be precise enough to change clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

Aug 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant women between 24 and 40 weeks of gestation. Exclusion Criteria: * Multiple gestation * Maternal vasculitis * Previous cesarean section (3 or more) * Brain or eye tumors * Neurological conditions * Chronic renal disease * Purpura * Heart disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-eclampsia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-eclampsia

Contacts and locations

Locations

  • Saint Thomas Hospital

    Panama City, Provincia de Panamá, Panama

More trials for these conditions

Other studies related to the condition(s) this trial covers.